Virpax Signs Extension to Develop NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative with NCATS
DENVER, Colo., Nov 22, 2024 (247marketnews.com)- Virpax Pharmaceuticals (NASDAQ: VRPX) stated that it was granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services, for the continued development of NES100, Virpax’s intranasal peptide product candidate, for the management of acute and chronic non-cancer pain.
Jatinder Dhaliwal, Virpax’s CEO, stated, “We are excited that this collaboration has been extended with NCATS and the NIH Helping to End Addiction Long-term (HEAL) initiative as we believe that it may help Virpax develop an effective and safe alternative to conventional opioids used by patients to manage acute and chronic pain. We believe that the NIH/NCATS collaborative agreement will enable our team to maintain momentum in both our pre-clinical and clinical development strategies.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (VRPX)
- MoBot’s Stock Market Highlights – 03/21/25 09:00 AM
- Virpax Pharmaceuticals Announces Reverse Stock Split
- 24/7 Market News Snapshot 19 March, 2025 – Virpax Pharmaceuticals, Inc. Common Stock (NASDAQ:VRPX)
- MoBot’s Stock Market Highlights – 03/19/25 07:00 AM
- Kraig Biocraft Laboratories (KBLB) Unlocks Revolutionary Opportunities in Energy and Defense Sectors with Advanced Spider Silk Technology